Pfizer stock price, PFE

Pfizer stock chart:



Pfizer close price: 33.64

Stock price forecast:

DOWN TO -1.78%
Target: 33.04

Total forecasts: 82
Reached: 17 (20.73%)

Total Win: 7.83 (24.18%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90831821.69%8.380.31%2,187.340.740.03%9.120.33%
3023730.43%2.630.33%542.173.930.72%6.560.84%
1415213.33%0.600.12%439.882.560.58%3.160.62%
7800.00%0.000.00%270.231.110.41%1.110.41%

Showing 1-10 of 551 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-04-2333.6433.030000-00-00
2017-04-2233.64330000-00-00
2017-04-2133.7433.030000-00-00
2017-04-2033.6132.990000-00-00
2017-04-1933.8433.410000-00-00
2017-04-183433.580000-00-00
2017-04-1733.8833.460000-00-00
2017-04-1633.8833.430000-00-00
2017-04-1533.8833.410000-00-00
2017-04-1433.8833.340000-00-00

Pfizer latest news:


  • 04/19/2017 14:03:02

    Pfizer is latest to get Justice Department subpoena in intravenous saline investigation

    Pfizer Inc. has been subpoenaed by the Justice Department as part of an antitrust investigation into intravenous saline sales practices, requests that it is "evaluating," the company said Wednesday. Saline is a salt water solution that's widely used in the medical system. The shortage caught attention in recent years, with manufacturers claiming they just couldn't keep up with demand. Prices rose 200% to 300% since the 2013 shortage, according to a letter sent by four senators to the Federal Trade Commission in late October 2015. Pfizer acquired Hospira, one of three main saline manufacturers, in September 2015. Wednesday's news follows a Tuesday disclosure by ICU Medical , which Pfizer completed a sale of its infusion therapy assets to in early February, that it had been subpoenaed in connection with an investigation. ICU Medical said it has also had a request from the New York Attorney General for information on its IV solution sales practices, and that "both of these investigations relate primarily to time periods prior to the Company's ownership." The subpoena called for "documents regarding the manufacturing, selling, pricing and shortages of intravenous ("IV") solutions, including saline, sold by the Company and communications with competitors regarding the same," ICU Medical said. Pfizer said in a March 16 financial filing that it was being sued in an Illinois district court for allegedly artificially raising prices of IV saline solution, with the lawsuit aiming for class action status. On Friday, another company, Baxter International Inc. , said that one of its employees had received agrand jury subpoena as part of an investigation into its saline sales practices. Pfizer shares slumped 0.6% in Wednesday afternoon trade. Shares have risen 6.2% over the last three months, compared with a 3.3% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/04/2017 07:08:41

    Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs

    Onconova Therapeutics Inc. stock surged as much as 18% in premarket trade Tuesday after the company said its two cancer drugs had positive pre-clinical results. Onconova shares were valued at $3.01 as of Monday's close. One drug, ON 123300, was found in a model to work as well as Pfizer Inc.'s Ibrance, and could lead to less infection susceptibility, the company said. The other drug, ON 150030, showed promising results in relapsed and refractory Acute Myeloid Leukemia, the company said. Both results were presented on Monday at the American Association for Cancer Research's annual meeting. Onconova shares have surged 30.3% over the last three months, compared with a 3.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/17/2017 16:41:03

    Momenta Pharma shares halted as drug application hits speed bump

    Momenta Pharmaceuticals Inc. were halted in the extended session Friday after the biotech company said a supplier's compliance issue could delay approval of a higher dose of one of its multiple sclerosis drugs. Momenta shares were halted at $19 after hours. The company said a key supplier of its Glatopa multiple sclerosis drug, Pfizer Inc. , was served with a Food and Drug Administration Warning Letter, meaning something at the Pfizer facility was not in compliance with FDA code. Until the facility demonstrates compliance, Momenta said that approval for its marketing application for a 40 mg. dose of Glatopa is "unlikely" in the first quarter. Pfizer shares declined 0.4% to $33.48 after hours.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/31/2017 13:01:32

    Pfizer Swings to 4Q Profit After Rough Year, Hikes 2017 View

    Drugmaker Pfizer Inc. is forecasting slightly higher sales and profit this year after a difficult 2016, though reduced spending on overhead and lawsuits helped it swing to a fourth-quarter profit, following a loss a year earlier

  • 01/31/2017 06:16:00

    Pfizer 4Q Profit Misses Estimates

    Pfizer, which closed its $14 billion acquisition of Medivation in September, reported a lower-than-expected profit, hit by lower demand for products set to go off patent.

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX+1.23% | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |